News

Accorto Regulatory Solutions Launches Dedicated Quality & Compliance Division

Accorto Regulatory Solutions, LLC (Accorto), a U.S.-based regulatory advisory firm, announced the launch of its dedicated Quality & Compliance Division, expanding the firm’s ability to deliver integrated regulatory and compliance support to organizations involved in the development of FDA-regulated products.

The new division formalizes and expands Accorto’s compliance and GxP services in response to growing client demand for coordinated quality and regulatory support. The dedicated structure enables Accorto to deliver focused compliance expertise while scaling services to meet evolving client needs, including GxP compliance, quality system development, inspection readiness, and ongoing compliance activities. These services complement the firm’s established regulatory strategy and FDA application development offerings, enabling more seamless engagement across regulatory and operational functions.

“As our clients’ needs have evolved, so have we,” said Tom Beaudet, Chief Executive Officer of Accorto Regulatory Solutions. “Formalizing our compliance services into a dedicated division allows us to take a more strategic, scalable approach while continuing to deliver the hands-on support our clients rely on. This launch reflects our long-term vision of being a truly full-service regulatory and compliance partner.”

The Quality & Compliance Division will be led by Kristina Haysmer, who has been named Vice President of Compliance Consulting. A foundational member of Accorto, Kristina has played a key role in shaping the firm’s growth and service offerings since its inception. In her new role, she will guide the strategic development of the division, ensuring alignment with client needs and Accorto’s long-term objectives.

“With the launch of this division, we are reinforcing our commitment to meeting clients where they are and supporting them at every stage,” said Kristina. “Our goal is to deliver seamless, integrated solutions that reduce complexity and help organizations operate with confidence in highly regulated markets.”

Read more.

Recent News

03/19/2026

GeneDx to Launch Genetic Testing Program with Zevra Therapeutics to Support Patients with Suspected Niemann-Pick Disease Type C

GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced a new genetic testing program with Zevra Therapeutics, Inc. (Nasdaq: ZVRA), a commercial-stage biopharmaceutical company focused on bringing life-changing therapeutics to people living with rare diseases. The Niemann-Pick Disease type C (NPC) Sponsored Genetic Testing

03/18/2026

Phlow Corp. Appoints Dawn Von Rohr as Chief Operating Officer to Advance Domestic Pharmaceutical Manufacturing

Phlow Corp., a leading American advanced pharmaceutical contract development and manufacturing organization (CDMO), today announced that Dawn Von Rohr has been appointed Chief Operating Officer (COO). Von Rohr will oversee Phlow’s operations, manufacturing execution, and strategic growth initiatives as the company continues expanding its advanced pharmaceutical development and manufacturing infrastructure in the United States to

03/17/2026

W&M Undergrads expand the chemical toolbox for cancer drugs

Thanks to modern therapies, a cancer diagnosis is no longer an automatic death sentence. But many patients still suffer from unwanted side effects and limited efficacy. In a recent Bioconjugate Chemistry publication, William & Mary researchers designed an antibody-drug conjugate (ADC) with the potential to improve the potency and decrease the cost of currently approved cancer drugs. Like